



國藥控股股份有限公司
SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國藥控股股份有限公司)
(於中華人民共和國註冊成立之股份有限公司，在香港以國藥控股股份有限公司之名稱經營業務)
(Stock Code 股份代號：01099)

25 April 2025

Dear Shareholder(s),

Reminder Letter regarding the Arrangement of Electronic Dissemination of Corporate Communications ^(Note 1)

With reference to the notification letter dated 8 February 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Sinopharm Group Co. Ltd. (the "Company") is writing to remind you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any document issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at sinopharm.todayir.com and the HKExnews's website at www.hkexnews.hk in place of notice of publication of Corporate Communications and printed copies (except for Actionable Corporate Communications ^(Note 2)).

Solicitation of electronic contact details

The Company has not received your email address for the electronic dissemination of Actionable Corporate Communications. To ensure timely receipt of future Actionable Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the reply form (the "Reply Form") on the reverse side. Alternatively, you may sign the Reply Form and return it to the Company c/o Computershare Hong Kong Investor Services Limited (the "H Share Registrar"), at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, the Company will send you future Actionable Corporate Communications in printed form.

If you want to receive future Corporate Communications in printed form, please complete the Reply Form and return it to the Company c/o the H Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, or send an email to sinopharm.ecom@computershare.com.hk specifying your name, address and request to receive future Corporate Communications in printed form. Please note that instructions made in this instance to receive future Corporate Communications in printed form shall be valid from the date of receipt and will remain valid until the instruction has been revoked or superseded or until the Company publishes its annual report in the following year (whichever is earlier).

Should you have any queries relating to any of the above matters, please call the Company's enquiry hotline at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
For and on behalf of
Sinopharm Group Co. Ltd.*
Zhao Bingxiang
Chairman

Note 1: This letter is addressed to registered shareholders of the Company who have not yet provided an email address for the timely receipt of actionable corporate communications. If you are a new registered shareholder, please read the arrangement for the electronic dissemination of corporate communications below and provide your email address as recommended.

Note 2: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder, including but not limited to election forms in connection with a dividend payment (e.g. choice of scrip or cash dividend, currency); excess application forms or provisional allotment letters in connection with a rights issue; and acceptance forms in connection with takeovers, mergers and share buy-backs (including acceptance forms in general offers and acceptance and approval form in partial offers).

各位股東：

以電子方式發佈公司通訊安排的提示信函 ^(附註1)

根據日期為2024年2月8日有關「以電子方式發佈公司通訊之安排」之通知信函所述，國藥控股股份有限公司（「公司」）謹此通知閣下，公司已採用以電子方式發佈公司通訊（「公司通訊」）之安排，該公司通訊是指公司向向其任何證券持有人或投資大眾提供資訊或提醒其採取行動而發佈或將要發佈的任何文件，包括但不限於(a)董事報告、年度賬目連同審計報告副本以及（如適用）財務摘要報告；(b)中期報告及（如適用）中期報告摘要；(c)會議通告；(d)上市文件；(e)通函；和(f)委任表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 sinopharm.todayir.com 和香港交易所披露易網站 www.hkexnews.hk 上提供，以代替有關公司通訊之發佈通知及印刷本(可供採取行動的公司通訊 ^(附註2) 除外)。

徵集電子聯絡資料

公司尚未收到閣下就接收可供採取行動的公司通訊提供電子郵件地址。為確保及時收到未來可供採取行動的公司通訊，公司建議閣下透過掃描本函背頁之回條（「回條」）上列印的閣下專屬二維碼來提供閣下的電子郵件地址。或者，閣下也可以簽署回條並經香港中央證券登記有限公司（「H股登記處」）交回公司，地址為香港灣仔皇后大道東183號合和中心17M樓。

如果公司沒有收到閣下的有效電子郵件地址，公司將向閣下發送未來可供採取行動的公司通訊之印刷本。

若閣下希望收取未來公司通訊之印刷本，請填妥回條並經H股登記處交回公司，地址為香港灣仔皇后大道東183號合和中心17M樓，或發送電子郵件至 sinopharm.ecom@computershare.com.hk，並註明閣下的姓名、地址以及收取未來公司通訊印刷本的要求。請注意，本次選擇收取未來公司通訊印刷版之指示由收悉日起將一直有效，直至指示被撤銷或取代，或直至公司於翌年刊發年報為止（以較早者為準）。

如閣下對本函內容有任何疑問，請致電公司電話查詢熱線(852) 2862 8688，辦公時間為星期一至五（香港公眾假期除外）上午9時正至下午6時正（香港時間）。

代表國藥控股股份有限公司
董事長
趙炳祥
謹啟

2025年4月25日

附註1: 此函件致尚未提供電子郵件地址以接收可供採取行動的公司通訊之公司登記股東。若閣下為新登記股東，請閱讀以下以電子方式發佈公司通訊的安排，並按建議提供閣下的電子郵件地址。

附註2: 可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊，例如有關派付股息的選擇表格（例如選擇以股息或現金股息、貨幣）、有關供股的額外申請表格及暫定配額通知書、有關收購、合併及股份回購的接納表格（包括全面要約的接納表格以及部分要約的接納及批准表格）。

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."
本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港公司。



REPLY FORM 回條

To: Computershare Hong Kong Investor Services Limited
(The “H Share Registrar”)
17M Floor, Hopewell Centre
183 Queen’s Road East, Wanchai, Hong Kong

致：香港中央證券登記有限公司
(「H 股登記處」)
香港灣仔皇后大道東 183 號
合和中心 17M 樓

(Please **choose ONLY ONE** of the options below)
(請從以下選項中只選擇其中一項)

Personalized QR Code
專屬二維碼

Option 1: Provide your email address for receipt of future Actionable Corporate Communications ^(Note 3) of the Company via electronic dissemination by scanning your personalized QR code

選項 1： 掃描 閣下專屬二維碼提供 閣下之電子郵件地址，以接收公司通過電子方式發佈的未來可供採取行動的公司通訊 ^(附註 3)

You are **NOT required** to return this Reply Form if you choose Option 1.
如選擇了選項 1，閣下無須交回本回條。

Option 2: I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications ^(Note 3) of the following listed company (the “Company”) via electronic dissemination.

選項 2: 本人/吾等現以書面提供本人/吾等之電子郵件地址，以確保收到公司通過電子方式發佈的未來可供採取行動的公司通訊 ^(附註 3)

Name of Securities holder(s) 證券持有人姓名：

Name of the listed company 上市公司名稱：

Sinopharm Group Co. Ltd.* (the “Company”)
國藥控股股份有限公司* (「公司」)

Email address 電郵地址：
^(Notes 1, 3&4 / 附註 1, 3&4)

Option 3: I/we hereby request for receipt of future Corporate Communications ^(Note 7) in printed form and noted that this instruction shall be valid from the receipt date and will remain valid until the instruction has been revoked or superseded or until the time when the Company publishes its annual report in the following year (whichever is earlier). ^(Note 5)
(Please mark “✓” in the below box if applicable)

選項 3： 本人/吾等現要求收取未來公司通訊 ^(附註 7) 印刷本，並已知悉本指示由收悉日起將一直有效，直至指示被撤銷或取代，或直至公司於翌年刊發年報為止（以較早者為準）。^(附註 5) (如適用，請在以下方格內劃上「✓」號)

☐ English Version 英文版本

☐ Chinese Version 中文版本

☐ English and Chinese Version 英文及中文版本

Signature(s): ^(Note 2)

簽名：(附註 2)

Contact number:

聯絡電話號碼：

Date:

日期：

Notes 附註：

- Please complete all your details clearly. You are reminded to use legible handwriting if you are filling in the information in writing.
請清楚填寫 閣下之所有資料，如 閣下以書面提供資料，閣下應注意字體清晰。
- Any Reply Form with no signature or otherwise incorrectly completed will be void. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.
任何回條若未有簽署或在其他方面填寫不正確，則本回條將作廢。如屬聯名股東，則本回條須由所有聯名股東聯合簽署，方為有效。
- If the Company does not receive a functional email address in your reply, the Company will send you future Actionable Corporate Communications in printed form. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder, including but not limited to election forms in connection with a dividend payment (e.g. choice of scrip or cash dividend, currency); excess application forms or provisional allotment letters in connection with a rights issue; and acceptance forms in connection with takeovers, mergers and share buy-backs (including acceptance forms in general offers and acceptance and approval form in partial offers).
如公司沒有收到 閣下的有效電子郵件地址，公司將向 閣下發送未來可供採取行動的公司通訊之印刷本。可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊，例如有關派付股息之選擇表格（例如選擇以股代息或現金股息、貨幣）、有關供股的額外申請表格及暫定配額通知書、有關收購、合併及股份回購的接納表格（包括全面要約的接納表格以及部分要約的接納及批准表格）。
- If you provide more than one email address, only the latest one email address provided will be registered.
如 閣下提供多於一個的電子郵件地址，只有 閣下最後提供的電子郵件地址將會被用於登記。
- If you mark “✓” in the box in Option 3, no email address will be registered and only Corporate Communications ^(Note 7) in printed form will be received.
如 閣下在選項 3 方格內劃上「✓」號，將不會有電子郵件地址被登記，只有公司通訊 ^(附註 7) 的印刷本會被收取。
- For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.
為免存疑，在本回條上的任何額外指示，公司將不予處理。
- Unless otherwise specified, Corporate Communications refer to any document issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.
除非另有註明，公司通訊乃指公司發佈或將要發佈以供其任何證券的持有人或投資大眾參照或採取行動的任何文件，包括但不限於(a) 董事報告、年度賬目連同審計報告副本以及 (如適用) 財務摘要報告；(b) 中期報告及 (如適用) 中期報告摘要；(c) 會議通知；(d) 上市文件；(e) 通函；和(f) 委任表格。

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”
公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港公司。

PERSONAL INFORMATION COLLECTION STATEMENT

收集個人資料聲明

- “Personal Data” in this statement has the same meaning as “personal data” in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong (“PDPO”).
本聲明中所指的「個人資料」與香港法例第 486 章《個人資料（私隱）條例》（「《私隱條例》」）中「個人資料」的定義相同。
- Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company’s electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form. 閣下於本回條所提供的個人資料將用於(包括但不限於)有關公司以電子方式發佈公司通訊及就 閣下持有的公司證券有關的其他事宜上與 閣下聯絡。閣下是自願向公司提供個人資料。若 閣下未能提供足夠資料，公司可能無法處理 閣下在本回條上所指示的指示及/或要求。
- Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the H Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
公司可就任何所說明的用途或在法例規定的情況下，將 閣下的個人資料披露或轉移給公司的附屬公司、H 股登記處、及/或其他公司或團體，並將在適當期間保留該等個人資料作核實及紀錄用途。
- You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the H Share Registrar at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong or by email at PrivacyOfficer@computershare.com.hk. 閣下有權根據《私隱條例》的條文查閱及/或修改 閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至 H 股登記處（地址為香港灣仔皇后大道東 183 號合和中心 17M 樓）向香港隱私主任提出，或發送電郵至 PrivacyOfficer@computershare.com.hk。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited
香港中央證券登記有限公司
Freeport No. 簡便回郵號碼：37
Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.
No postage is necessary if posted in Hong Kong.

當 閣下寄回此回條時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。